GLOBUS MEDICAL news

GMED has a Zacks Rank #1 (Strong Buy), lower forward P/E of 14.88, PEG ratio of 1.19, and Value grade of B, indicating stronger earnings outlook and better valuation metrics compared to its peer.

Medical device company with 8.8% expected sales growth for 2026, Zacks Rank #1 rating, and strong market presence across 65 countries. Selected as a reliable sales growth stock with solid business fundamentals.

Strong Buy rating (Zacks Rank #1), superior Value grade (B), lower forward P/E ratio (16.86), lower PEG ratio (1.35), and stronger earnings outlook improvement compared to peer

The acquisition of Higgs Boson Health represents strategic growth and expansion of Globus Medical's digital healthcare capabilities. The deal brings experienced software developers and AI scientists to strengthen their ecosystem and advance their vision of improving patient outcomes. This is presented as a positive step in their long-term strategy.

Zacks Rank #1 with Q2 2026 EPS beat of 19.6%, consistent quarterly outperformance (average 27.9% surprise), and strong long-term earnings growth rate of 12.4%.

Zacks Rank #1 (Strong Buy) with excellent earnings beat history (average 27.9% surprise over trailing four quarters). Q2 2026 EPS beat consensus by 19.6%. Long-term estimated earnings growth rate of 12.4% indicates sustained positive momentum.

Globus Medical is rated Zacks Rank #1 (Strong Buy) with a strong earnings yield of 6.8%, consistent earnings beats averaging 27.9% surprise, and robust stock performance of 32.6% year-to-date.

Globus Medical carries a Zacks Rank #2 (Buy) with strong recent performance, beating earnings estimates by 19.6% and revenue estimates by 0.4% in Q2 2026, with consistent earnings beats over trailing four quarters.

Zacks Rank #1 (Strong Buy) with highest earnings yield (6.7% vs industry -1.4%), consistent quarterly earnings beats (27.9% average surprise), and solid stock appreciation (+27.3% vs industry -3.8%).

Zacks Rank #1 (Strong Buy) with consistent earnings beats (27.9% average surprise across trailing four quarters), Q2 EPS beat of 19.6%, and 12.4% estimated long-term earnings growth rate demonstrate strong operational execution and growth trajectory.

Mentioned as a better-ranked alternative stock in the medical space with Zacks Rank #1, but no direct connection to the main news story about Natera's approval.

Zacks Rank #1 with strong Q2 2026 earnings beat of 19.6% and consistent outperformance. Long-term earnings growth rate of 12.4% and average earnings surprise of 27.9% over trailing four quarters.

Zacks Rank #1 with earnings yield of 6.7% versus industry's negative 1.4%. Shares rallied 30.7% with consistent earnings beats averaging 27.9% surprise.

Zacks Rank #2 (Buy) with strong Q2 performance: adjusted EPS of $1.34 beat consensus by 19.6%, revenues beat by 0.4%, consistent earnings beats with 27.9% average surprise, and 12.4% estimated long-term earnings growth.

Globus Medical secured CE Mark for Excelsius3D, an advanced intraoperative imaging platform combining multiple imaging modalities, expanding its product portfolio and market reach in surgical imaging.

Company beat earnings estimates by 19.6% and revenue estimates by 0.4% in Q2 2026, with consistent earnings beats over trailing four quarters (27.9% average surprise) and estimated long-term earnings growth of 12.4%.

Zacks Rank #2 (Buy) with earnings beat of 19.6% above consensus and revenue beat of 0.4%. Consistent earnings outperformance with 27.9% average surprise over trailing four quarters and 12.4% estimated long-term earnings growth rate.

Zacks Rank #1 (Strong Buy) with highest earnings yield (6.7% vs industry -1.4%), consistent earnings outperformance (27.9% average surprise), and strong share appreciation (+27.3% vs industry +3.8%).

Zacks Rank #2 (Buy) with strong Q2 2026 earnings beat (19.6% above consensus) and consistent outperformance, featuring 12.4% estimated long-term earnings growth rate.

Zacks Rank #2 (Buy) with strong financial performance: Q2 2026 EPS beat estimates by 19.6%, revenues beat by 0.4%. Consistent earnings beats in trailing four quarters with 27.9% average surprise. Long-term earnings growth rate of 12.4%.

Zacks Rank #1 (Strong Buy) with 27.3% share price gain, 6.7% earnings yield significantly above industry average, and consistent earnings beats with 27.9% average surprise.

GMED holds a Zacks Rank #1 (Strong Buy) with perfect earnings beat record (4 of 4 quarters) and exceptional average surprise of 27.9%, plus projected 8.8% revenue growth.

Highlighted as a top-ranked medical stock with Zacks Rank #1. Reported Q2 2026 adjusted EPS beat of 19.6% and long-term earnings growth rate of 12.4%, with consistent quarterly outperformance.

Highlighted as a better-ranked medical stock with Zacks Rank #2 (Buy). Reported Q2 2026 adjusted EPS of $1.34, beating estimates by 19.6%, with revenues beating by 0.4%. Demonstrates consistent outperformance with 27.9% average earnings surprise over trailing four quarters.